Copeptin

Last updated

Copeptin
Copeptine pour wikipedia.png
Diagram of the pre-pro-vasopressin precursor showing position and size in amino acids of AVP, neurophysin II and copeptin
Identifiers
SymbolCT-proAVP
Alt. symbolscopeptine
OMIM 192340
UniProt P01185
Other data
Locus Chr. 20 p13

Copeptin (also known as CT-proAVP) is a 39-amino acid-long peptide derived from the C-terminus of pre-pro-hormone of arginine vasopressin, neurophysin II and copeptin. Arginine vasopressin (AVP), also known as the antidiuretic hormone (ADH), is encoded by the AVP gene and is involved in multiple cardiovascular and renal pathways and abnormal level of AVP are associated with various diseases. Hence measurement of AVP would be useful, but is not commonly carried out in clinical practice because of its very short half-life making it difficult to quantify. In contrast, copeptin can be immunologically tested with ease and therefore can be used as a vasopressin surrogate marker.

Contents

Synthesis and secretion

Copeptin is a 39-amino acid-long, glycosylated peptide. [1] It is synthesized mainly in the paraventricular neurons of the hypothalamus and in the supraoptic nucleus. [2] During axonal transport, pre-pro-AVP is proteolytically cleaved into vasopressin, neurophysin II and copeptin. [3] These molecules are then stored in secretory granules in the posterior pituitary and released upon osmotic or non-osmotic (hemodynamical; stress-related) stimuli. [2]

Function

Once secreted into the bloodstream, there is no known biological role for copeptin. However, when pre-pro-vasopressin is processed during the axonal transport, copeptin may contribute to the 3D folding of vasopressin. [2]

Surrogate vasopressin marker

The size and half-life of copeptin permit an easier immunological testing, compared to vasopressin, and hence copeptin is proposed as a reliable AVP surrogate. [4] [5] The clinical interest in copeptin testing is closely linked to the pathophysiological pathways in which vasopressin is involved: polydipsia-polyuria syndrome, hyponatremia, syndrome of inappropriate antidiuretic hormone secretion (SIADH) as well as heart failure and acute coronary syndrome. [6]

In blood

The concentration of copeptin in the blood circulation ranges from 1 to 12 pmol/L in healthy individuals. [6] The levels of copeptin are slightly higher in men than in women [6] and are not influenced by age. [6] In response to serum osmolality fluctuations, the kinetics of copeptin are comparable to those of vasopressin. [6] [7] For example, patients with an electrolyte disorders such as diabetes insipidus with very low vasopressin concentrations also show very low copeptin concentrations in blood plasma. [8] On the other hand, patients suffering from syndrome of inappropriate antidiuretic hormone secretion show high concentrations of both vasopressin and copeptin. [9]

Acute myocardial infarction

Several studies have shown that copeptin is released very early during the onset of an acute myocardial infarction (AMI), [10] [11] raising the question of its potential value in the diagnosis of AMI and particularly in ruling-out AMI. [11] [12] [13] Indeed, copeptin is released much earlier than troponin, given that copeptin is actively released from the hypothalamus, while troponin occurs in the bloodstream as a breakdown product from dying cardiomyocytes, [14] making the interpretation of their complementary kinetics a useful tool to rule-out AMI. [11] [12] It has been shown that the combination of a negative result of troponin together with a negative result of copeptin can rule out AMI at emergency department presentation with a negative predictive value ranging from 95% to 100%. [11] [12] [13] These results have been confirmed in a randomised controlled trial. [15] [16] [17]

Cardiogenic shock

High concentrations of vasopressin during cardiogenic shock have been widely described. [18] [19] It has been shown that the kinetics of copeptin are similar to vasopressin in that context. [20]

Heart failure

The prognostic value of vasopressin for prediction of outcome in patients suffering from heart failure has been known since the nineties. Patients presenting with high levels of vasopressin have a worsened outcome. [21] [22] Recently, a similar interest has been demonstrated for copeptin in heart failure. [10] [23] [24] [25]

See also

Related Research Articles

Vasopressin Mammalian hormone released from the pituitary gland

Vasopressin, also called antidiuretic hormone (ADH), arginine vasopressin (AVP) or argipressin, is a hormone synthesized from the AVP gene as a peptide prohormone in neurons in the hypothalamus, and is converted to AVP. It then travels down the axon of that cell, which terminates in the posterior pituitary, and is released from vesicles into the circulation in response to extracellular fluid hypertonicity (hyperosmolality). AVP has two primary functions. First, it increases the amount of solute-free water reabsorbed back into the circulation from the filtrate in the kidney tubules of the nephrons. Second, AVP constricts arterioles, which increases peripheral vascular resistance and raises arterial blood pressure.

Troponin Protein complex

Troponin, or the troponin complex, is a complex of three regulatory proteins that are integral to muscle contraction in skeletal muscle and cardiac muscle, but not smooth muscle. Measurements of cardiac-specific troponins I and T are extensively used as diagnostic and prognostic indicators in the management of myocardial infarction and acute coronary syndrome. Blood troponin levels may be used as a diagnostic marker for stroke, although the sensitivity of this measurement is low.

Cardiac markers are biomarkers measured to evaluate heart function. They can be useful in the early prediction or diagnosis of disease. Although they are often discussed in the context of myocardial infarction, other conditions can lead to an elevation in cardiac marker level.

Acute coronary syndrome Medical condition

Acute coronary syndrome (ACS) is a syndrome due to decreased blood flow in the coronary arteries such that part of the heart muscle is unable to function properly or dies. The most common symptom is centrally located chest pain, often radiating to the left shoulder or angle of the jaw, crushing, central and associated with nausea and sweating. Many people with acute coronary syndromes present with symptoms other than chest pain, particularly women, older patients, and patients with diabetes mellitus.

In cardiology, ventricular remodeling refers to changes in the size, shape, structure, and function of the heart. This can happen as a result of exercise or after injury to the heart muscle. The injury is typically due to acute myocardial infarction, but may be from a number of causes that result in increased pressure or volume, causing pressure overload or volume overload on the heart. Chronic hypertension, congenital heart disease with intracardiac shunting, and valvular heart disease may also lead to remodeling. After the insult occurs, a series of histopathological and structural changes occur in the left ventricular myocardium that lead to progressive decline in left ventricular performance. Ultimately, ventricular remodeling may result in diminished contractile (systolic) function and reduced stroke volume.

Unstable angina (UA), also called crescendo angina, is a type of angina pectoris that is irregular. It is also classified as a type of acute coronary syndrome (ACS).

Acute pericarditis Medical condition

Acute pericarditis is a type of pericarditis usually lasting less than 6 weeks. It is the most common condition affecting the pericardium.

Bivalirudin

Bivalirudin (Bivalitroban), sold under the brand names Angiomax and Angiox and manufactured by The Medicines Company, is a direct thrombin inhibitor (DTI).

Vasotocin Chemical compound

Vasotocin is an oligopeptide homologous to oxytocin and vasopressin found in all non-mammalian vertebrates and possibly in mammals during the fetal stage of development. Arginine vasotocin (AVT), a hormone produced by neurosecretory cells within the posterior pituitary gland (neurohypophysis) of the brain, is a major endocrine regulator of water balance and osmotic homoeostasis and is involved in social and sexual behavior in non-mammalian vertebrates. In mammals, it appears to have biological properties similar to those of oxytocin and vasopressin. It has been found to have effects on the regulation of REM sleep. Evidence for the existence of endogenous vasotocin in mammals is limited and no mammalian gene encoding vasotocin has been confirmed.

The ST2 cardiac biomarker is a protein biomarker of cardiac stress encoded by the IL1RL1 gene. ST2 signals the presence and severity of adverse cardiac remodeling and tissue fibrosis, which occurs in response to myocardial infarction, acute coronary syndrome, or worsening heart failure.

Myocardial infarction Interruption of blood supply to a part of the heart

A myocardial infarction (MI), commonly known as a heart attack, occurs when blood flow decreases or stops to the coronary artery of the heart, causing damage to the heart muscle. The most common symptom is chest pain or discomfort which may travel into the shoulder, arm, back, neck or jaw. Often it occurs in the center or left side of the chest and lasts for more than a few minutes. The discomfort may occasionally feel like heartburn. Other symptoms may include shortness of breath, nausea, feeling faint, a cold sweat or feeling tired. About 30% of people have atypical symptoms. Women more often present without chest pain and instead have neck pain, arm pain or feel tired. Among those over 75 years old, about 5% have had an MI with little or no history of symptoms. An MI may cause heart failure, an irregular heartbeat, cardiogenic shock or cardiac arrest.

Cardiorenal syndrome (CRS) is an umbrella term used in the medical field that defines disorders of the heart and kidneys whereby “acute or chronic dysfunction in one organ may induce acute or chronic dysfunction of the other”. The heart and the kidneys are involved in maintaining hemodynamic stability and organ perfusion through an intricate network. These two organs communicate with one another through a variety of pathways in an interdependent relationship. In a 2004 report from National Heart, Lung and Blood Institute, CRS was defined as a condition where treatment of congestive heart failure is limited by decline in kidney function. This definition has since been challenged repeatedly but there still remains little consensus over a universally accepted definition for CRS. At a consensus conference of the Acute Dialysis Quality Initiative (ADQI), the CRS was classified into five subtypes primarily based upon the organ that initiated the insult as well as the acuity of disease.

Heart-type fatty acid binding protein

Heart-type fatty acid binding protein (hFABP) also known as mammary-derived growth inhibitor is a protein that in humans is encoded by the FABP3 gene.

Electrocardiography in myocardial infarction

Electrocardiography in suspected myocardial infarction has the main purpose of detecting ischemia or acute coronary injury in emergency department populations coming for symptoms of myocardial infarction (MI). Also, it can distinguish clinically different types of myocardial infarction.

Francis M. Fesmire American emergency physician (1969–2014)

Francis Miller Fesmire was an American emergency physician and a nationally recognized expert in myocardial infarction. He authored numerous academic articles and assisted in the development of clinical guidelines on the standard of care in treating patients with suspected myocardial infarction by the American College of Emergency Physicians and the American Heart Association/American College of Cardiology. He performed numerous research investigations in chest pain patients, reporting the usefulness of continuous 12-lead ECG monitoring, two-hour delta cardiac marker testing, and nuclear cardiac stress testing in the emergency department. The culmination of his studies was The Erlanger Chest Pain Evaluation Protocol published in the Annals of Emergency Medicine in 2002. In 2011 he published a novel Nashville Skyline that received a 5 star review by ForeWord Reviews. His most recent research involved the risk stratification of chest pain patients in the emergency department.

A diagnosis of myocardial infarction is created by integrating the history of the presenting illness and physical examination with electrocardiogram findings and cardiac markers. A coronary angiogram allows visualization of narrowings or obstructions on the heart vessels, and therapeutic measures can follow immediately. At autopsy, a pathologist can diagnose a myocardial infarction based on anatomopathological findings.

Kounis syndrome is defined as acute coronary syndrome caused by an allergic reaction or a strong immune reaction to a drug or other substance. It is a rare syndrome with authentic cases reported in 130 males and 45 females, as reviewed in 2017; however, the disorder is suspected of being commonly overlooked and therefore much more prevalent. Mast cell activation and release of inflammatory cytokines as well as other inflammatory agents from the reaction leads to spasm of the arteries leading to the heart muscle or a plaque breaking free and blocking one or more of those arteries.

Remote ischemic conditioning (RIC) is an experimental medical procedure that aims to reduce the severity of ischaemic injury to an organ such as the heart or the brain, most commonly in the situation of a heart attack or a stroke, or during procedures such as heart surgery when the heart may temporary suffer ischaemia during the operation, by triggering the body's natural protection against tissue injury. Although noted to have some benefits in experimental models in animals, this is still an experimental procedure in humans and initial evidence from small studies have not been replicated in larger clinical trials. Successive clinical trials have failed to identify evidence supporting a protective role in humans.

Vasopressin (medication)

Vasopressin infusions are in use for septic shock patients not responding to fluid resuscitation or infusions of catecholamines to increase the blood pressure while sparing the use of catecholamines. These argipressins have much shorter elimination half-life comparing to synthetic non-arginine vasopresines with much longer elimination half-life of many hours. Further, argipressins act on V1a, V1b, and V2 receptors which consequently lead to higher eGFR and lower vascular resistance in the lungs. A number of injectable arginine vasopressins are in clinical use in the United States and the European Union. Pitressin among others, is a medication most commonly used in the treatment of frequent urination, increased thirst, and dehydration such as that resulting from diabetes insipidus, which causes increased and diluted urine. It is used to treat abdominal distension following some surgeries, and in stomach roentgenography. Vasopressin is a hormone that affects the kidneys and reduces urine flow.

Ventricular natriuretic peptide

Ventricular natriuretic peptide or brain natriuretic peptide (BNP), also known as B-type natriuretic peptide, is a hormone secreted by cardiomyocytes in the heart ventricles in response to stretching caused by increased ventricular blood volume.

References

  1. ↑ Land H, Schütz G, Schmale H, Richter D (January 1982). "Nucleotide sequence of cloned cDNA encoding bovine arginine vasopressin-neurophysin II precursor". Nature. 295 (5847): 299–303. Bibcode:1982Natur.295..299L. doi:10.1038/295299a0. PMID   6276766. S2CID   4340962.
  2. 1 2 3 Acher R, Chauvet J, Rouille Y (June 2002). "Dynamic processing of neuropeptides: sequential conformation shaping of neurohypophysial preprohormones during intraneuronal secretory transport". Journal of Molecular Neuroscience. 18 (3): 223–8. doi:10.1385/JMN:18:3:223. PMID   12059040. S2CID   45410716.
  3. ↑ Repaske DR, Medlej R, Gültekin EK, Krishnamani MR, Halaby G, Findling JW, Phillips JA (January 1997). "Heterogeneity in clinical manifestation of autosomal dominant neurohypophyseal diabetes insipidus caused by a mutation encoding Ala-1-->Val in the signal peptide of the arginine vasopressin/neurophysin II/copeptin precursor". The Journal of Clinical Endocrinology and Metabolism. 82 (1): 51–6. doi: 10.1210/jcem.82.1.3660 . PMID   8989232.
  4. ↑ Robertson GL, Mahr EA, Athar S, Sinha T (September 1973). "Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma". The Journal of Clinical Investigation. 52 (9): 2340–52. doi:10.1172/JCI107423. PMC   333039 . PMID   4727463.
  5. ↑ Preibisz JJ, Sealey JE, Laragh JH, Cody RJ, Weksler BB (1983). "Plasma and platelet vasopressin in essential hypertension and congestive heart failure". Hypertension. 5 (2 Pt 2): I129-38. doi: 10.1161/01.hyp.5.2_pt_2.i129 . PMID   6826223.
  6. 1 2 3 4 5 Morgenthaler NG, Struck J, Jochberger S, Dünser MW (March 2008). "Copeptin: clinical use of a new biomarker". Trends in Endocrinology and Metabolism. 19 (2): 43–9. doi:10.1016/j.tem.2007.11.001. PMID   18291667. S2CID   6008127.
  7. ↑ Szinnai G, Morgenthaler NG, Berneis K, Struck J, Müller B, Keller U, Christ-Crain M (October 2007). "Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects". The Journal of Clinical Endocrinology and Metabolism. 92 (10): 3973–8. doi: 10.1210/jc.2007-0232 . PMID   17635944.
  8. ↑ Katan M, Morgenthaler NG, Dixit KC, Rutishauser J, Brabant GE, Müller B, Christ-Crain M (July 2007). "Anterior and posterior pituitary function testing with simultaneous insulin tolerance test and a novel copeptin assay". The Journal of Clinical Endocrinology and Metabolism. 92 (7): 2640–3. doi: 10.1210/jc.2006-2046 . PMID   17426098.
  9. ↑ Fenske W, Störk S, Blechschmidt A, Maier SG, Morgenthaler NG, Allolio B (January 2009). "Copeptin in the differential diagnosis of hyponatremia". The Journal of Clinical Endocrinology and Metabolism. 94 (1): 123–9. doi: 10.1210/jc.2008-1426 . PMID   18984663.
  10. 1 2 Khan SQ, Dhillon OS, O'Brien RJ, Struck J, Quinn PA, Morgenthaler NG, et al. (April 2007). "C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study". Circulation. 115 (16): 2103–10. doi: 10.1161/CIRCULATIONAHA.106.685503 . PMID   17420344.
  11. 1 2 3 4 Reichlin T, Hochholzer W, Stelzig C, Laule K, Freidank H, Morgenthaler NG, et al. (June 2009). "Incremental value of copeptin for rapid rule out of acute myocardial infarction". Journal of the American College of Cardiology. 54 (1): 60–8. doi: 10.1016/j.jacc.2009.01.076 . PMID   19555842.
  12. 1 2 3 Keller T, Tzikas S, Zeller T, Czyz E, Lillpopp L, Ojeda FM, et al. (May 2010). "Copeptin improves early diagnosis of acute myocardial infarction". Journal of the American College of Cardiology. 55 (19): 2096–106. doi: 10.1016/j.jacc.2010.01.029 . PMID   20447532.
  13. 1 2 Maisel A, Mueller C, Neath SX, Christenson RH, Morgenthaler NG, McCord J, et al. (July 2013). "Copeptin helps in the early detection of patients with acute myocardial infarction: primary results of the CHOPIN trial (Copeptin Helps in the early detection Of Patients with acute myocardial INfarction)". Journal of the American College of Cardiology. 62 (2): 150–160. doi: 10.1016/j.jacc.2013.04.011 . PMID   23643595.
  14. ↑ Boeckel JN, Oppermann J, Anadol R, Fichtlscherer S, Zeiher AM, Keller T (February 2016). "Analyzing the Release of Copeptin from the Heart in Acute Myocardial Infarction Using a Transcoronary Gradient Model". Scientific Reports. 6: 20812. Bibcode:2016NatSR...620812B. doi:10.1038/srep20812. PMC   4749978 . PMID   26864512.
  15. ↑ BIC-8 Archived 6 December 2013 at the Wayback Machine , on Site ESC2013 Archived 9 November 2013 at the Wayback Machine . On 10 September 2013
  16. ↑ Results of BIC-8 Archived 3 March 2016 at the Wayback Machine , on Site biomarqueursinfos.fr Archived 10 January 2016 at the Wayback Machine . On 10 November 2013
  17. ↑ Interview of principal investigator and ESC reviewer on BIC-8 Archived 4 March 2016 at the Wayback Machine , on Site biomarqueursinfos.fr Archived 10 January 2016 at the Wayback Machine . On 10 November 2013
  18. ↑ Lindner KH, Strohmenger HU, Ensinger H, Hetzel WD, Ahnefeld FW, Georgieff M (October 1992). "Stress hormone response during and after cardiopulmonary resuscitation". Anesthesiology. 77 (4): 662–8. doi:10.1097/00000542-199210000-00008. PMID   1329579.
  19. ↑ Krismer AC, Wenzel V, Stadlbauer KH, Mayr VD, Lienhart HG, Arntz HR, Lindner KH (September 2004). "Vasopressin during cardiopulmonary resuscitation: a progress report". Critical Care Medicine. 32 (9 Suppl): S432-5. doi:10.1097/01.CCM.0000134267.91520.C0. PMID   15508673. S2CID   36476296.
  20. ↑ Arnauld E, Czernichow P, Fumoux F, Vincent JD (November 1977). "The effects of hypotension and hypovolaemia on the liberation of vasopressin during haemorrhage in the unanaesthetized monkey (Macaca mulatta)". Pflügers Archiv. 371 (3): 193–200. doi:10.1007/bf00586258. PMID   414200. S2CID   24651230.
  21. ↑ Rouleau JL, de Champlain J, Klein M, Bichet D, Moyé L, Packer M, et al. (August 1993). "Activation of neurohumoral systems in postinfarction left ventricular dysfunction". Journal of the American College of Cardiology. 22 (2): 390–8. doi: 10.1016/0735-1097(93)90042-y . PMID   8101532.
  22. ↑ Rouleau JL, Packer M, Moyé L, de Champlain J, Bichet D, Klein M, Rouleau JR, Sussex B, Arnold JM, Sestier F (September 1994). "Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril". Journal of the American College of Cardiology. 24 (3): 583–91. doi: 10.1016/0735-1097(94)90001-9 . PMID   7915733.
  23. ↑ Konstam MA, Gheorghiade M, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C (March 2007). "Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial". JAMA. 297 (12): 1319–31. doi: 10.1001/jama.297.12.1319 . PMID   17384437.
  24. ↑ Gheorghiade M, Konstam MA, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C (March 2007). "Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials". JAMA. 297 (12): 1332–43. doi: 10.1001/jama.297.12.1332 . PMID   17384438.
  25. ↑ Neuhold S, Huelsmann M, Strunk G, Stoiser B, Struck J, Morgenthaler NG, Bergmann A, Moertl D, Berger R, Pacher R (July 2008). "Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease". Journal of the American College of Cardiology. 52 (4): 266–72. doi: 10.1016/j.jacc.2008.03.050 . PMID   18634981.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.